Given the performance in the third quarter of 2012, Merck is updating its forecast for FY 2012. Merck expects the markets for pharmaceuticals as well as over-the-counter drugs to grow driven by volumes in Emerging Markets. The company expects demand for its liquid crystals products in the fourth quarter to soften sequentially resulting in the Performance Materials division’s EBITDA pre being around last year’s fourth quarter. Finally, Merck continues to see solid demand for Life Science products, driven also by continued volume growth in biologic-based drugs.
Based on these assumptions, Merck expects the following financial performance of its divisions for FY 2012:
| XLS |
|
Guidance FY 2012 | ||||
|
|
|
| ||
|
|
|
| ||
|
|
|
| ||
|
Merck Divisions |
€ million |
EBITDA pre one-time items | ||
| ||||
|
Merck Serono |
|
~ 1,750 – 1,800 | ||
|
Consumer Health |
|
~ 60 | ||
|
Performance Materials |
|
~ 700 | ||
|
Merck Millipore |
|
~ 590 – 600 | ||
|
Corporate and Other |
|
~ –200 | ||
|
|
|
| ||
|
|
|
| ||
|
Merck Group |
€ billion |
| ||
|
Total revenues |
|
~ 10.9 – 11.0 | ||
|
EBITDA pre one-time items* |
|
2.90 – 2.95 | ||
FX assumptions for Q4 2012:
€/US$ = 1.29
€/CHF = 1.20
back
